Economic and Quality Of Life Impact of Dry Eye Symptoms in Women with Sjögren’s Syndrome

2002 ◽  
pp. 1183-1188 ◽  
Author(s):  
R. M. Sullivan ◽  
J. M. Cermak ◽  
A. S. Papas ◽  
M. R. Dana ◽  
D. A. Sullivan
Keyword(s):  
Quality Of Life ◽  
Sjögren’S Syndrome ◽  
Dry Eye ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Life Impact ◽  
Eye Symptoms ◽  
Dry Eye Symptoms ◽  
Sjögren‘S Syndrome

ECONOMIC AND QUALITY OF LIFE IMPACT OF DRY EYE SYMPTOMS IN WOMEN WITH SJÖGREN'S SYNDROME.

Cornea ◽  
2000 ◽  
Vol 19 (Supplement 2) ◽  
pp. S127
Author(s):  
R M Sullivan ◽  
J M Cermak ◽  
A S Papas ◽  
M R Dana ◽  
D A Sullivan
Keyword(s):  
Quality Of Life ◽  
Dry Eye ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Life Impact ◽  
Eye Symptoms ◽  
Dry Eye Symptoms ◽  
Sjögren‘S Syndrome

scholarly journals Ocular Surface Disease in Sjögren's Syndrome: Management in a Scleral Lens Clinical Practice

2020 ◽  
Vol 4 (1) ◽  
pp. e12-e22
Author(s):  
Daddi Fadel ◽  
Melissa Barnett
Keyword(s):  
Quality Of Life ◽  
Sjögren’S Syndrome ◽  
Dry Eye ◽  
Ocular Surface ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Autologous Serum ◽  
Sjögren‘S Syndrome

Sjögren’s syndrome is a chronic, autoimmune, systemic disease characterized by lymphocytic infiltration and malfunction of the exocrine glands, primarily the lacrimal and salivary glands, resulting in predominant symptoms of dry eye and dry mouth. Sjögren’s syndrome is a highly prevalent condition and is one of the most common systemic, rheumatic, autoimmune diseases, affecting up to 1.4% of adults in the United States, second only to rheumatoid arthritis in its prevalence in North America. Primary Sjögren’s syndrome has shown to affect patients’ health-related quality-of-life due to dryness, chronic pain, depression, anxiety,physical and mental fatigue, and neuropsychiatric symptoms. Scleral lenses (SLs) have shown to be significantly beneficial in relieving symptoms and improvingquality-of-life in patients with Sjögren’s syndrome and dry eye disease. SLs may be used concurrently with the other therapies including ocular lubricants, eyelid hygiene, punctal occlusion, topical prescription medications, and autologous serum. This manuscript reviews the implication of Sjögren’s syndrome on the ocular surface and quality-of-life and describes how SLs, in combination with other treatments, may be beneficial.

What Ophthalmologists Should Know About Sjögren’s Syndrome

2010 ◽  
Vol 04 (01) ◽  
pp. 77 ◽  
Author(s):  
Canan Asli Utine ◽  
Esen K Akpek ◽  
◽  
◽  
Keyword(s):  
Salivary Gland ◽  
Sjögren’S Syndrome ◽  
Dry Eye ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Autologous Serum ◽  
Eye Symptoms ◽  
Dry Eye Symptoms ◽  
Sjögren‘S Syndrome

About one-quarter of patients with dry-eye syndrome (DES) have an underlying rheumatic condition, most commonly Sjogren’s syndrome (SS). SS is a common, frequently underdiagnosed cause of dry eye with multisystemic involvement. The immunological background of SS involves activation of both innate and acquired immune systems. According to the 2002 American and European classification systems, presence of any four of the six criteria (i.e. symptoms of dry eye, symptoms of dry mouth, ocular signs of dry eye, objective salivary gland involvement, typical histopathology findings in minor salivary gland biopsy specimens and presence of serum autoantibodies) as long as either the biopsy or serology is positive or presence of any three of the four objective criteria is considered diagnostic of SS. The main goal of treatment of ocular involvement is the alleviation of dry-eye symptoms with replacement therapy, stimulation of tear secretion and supportive surgical procedures to conserve tears. Preservative-free tear substitutes, topical steroids, cyclosporine A, autologous serum eye-drops and punctal plugs are commonly used for this purpose.

Correlation between corneal sensitivity, subjective dry eye symptoms and corneal staining in Sjögren's syndrome

2004 ◽  
Vol 39 (7) ◽  
pp. 767-771 ◽  
Author(s):  
Feisal A. Adatia ◽  
Adi Michaeli-Cohen ◽  
Joel Naor ◽  
Barbara Caffery ◽  
Arthur Bookman ◽  
...  
Keyword(s):  
Sjögren’S Syndrome ◽  
Dry Eye ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Corneal Sensitivity ◽  
Eye Symptoms ◽  
Corneal Staining ◽  
Dry Eye Symptoms ◽  
Sjögren‘S Syndrome

scholarly journals Assessment of the Compliance with 0.1% Cyclosporine A in Dry-Eye Patients with Sjögren's Syndrome

2021 ◽  
Vol 62 (7) ◽  
pp. 895-903
Author(s):  
Do Hee Park ◽  
Hyung Nam Jin ◽  
Hee Su Yoon ◽  
Hyeon Jeong Yoon ◽  
Kyung-Chul Yoon
Keyword(s):  
Sjögren’S Syndrome ◽  
Dry Eye ◽  
Cyclosporine A ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Eye Drops ◽  
Eye Symptoms ◽  
Dry Eye Symptoms ◽  
Sjögren‘S Syndrome

Purpose: To evaluate the compliance with 0.1% cyclosporine A in dry eye patients with Sjögren's syndrome and identify factors affecting the compliance. Methods: This study included 67 dry eye patients with Sjögren's syndrome who had used 0.1% cyclosporine A for over 6 months. Clinical parameters including sex, age, the number of eye drops used, side effects, the use of steroid eye drops, and the visit interval were investigated. Additionally, the ocular surface disease index, tear break-up time (TBUT), Schirmer test score, and corneal fluorescein staining (CFS) score were assessed. Patients were classified into compliant and non-compliant groups, using a criterion of 50% compliance; relevant factors were evaluated accordingly. Results: Of the 67 patients, 36 (53.7%) were classified into the compliant group and 31 (46.3%) into the non-compliant group. Compared to the non-compliant group, the compliant group showed a longer TBUT (p = 0.03) and a lower CFS score (p = 0.04) at 6 months of follow-up. Altogether, 39 subjects (58.2%) experienced side effects, of which the most common was stinging pain (71.8%). In the multivariate analysis, severe dry-eye symptoms (p = 0.03), non-use of the steroid eye drops (p = 0.02), and longintervals between exam vitists (p = 0.02) were identified as factors reducing compliance. Conclusions: Factors related to a decrease in the compliance with 0.1% cyclosporine A in dry-eye patients with Sjögren's syndrome, included severe dry eye symptoms, long visit intervals, and non-use of steroid eye drops. Taking these factors into consideration may help increase patient compliance.

scholarly journals Economic burden and loss of quality of life from dry eye disease in Canada

2021 ◽  
Vol 6 (1) ◽  
pp. e000709
Author(s):  
Clara Chan ◽  
Setareh Ziai ◽  
Varun Myageri ◽  
James G Burns ◽  
C Lisa Prokopich
Keyword(s):  
Quality Of Life ◽  
Disease Severity ◽  
Sjögren’S Syndrome ◽  
Sjögren's Syndrome ◽  
Indirect Costs ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Eye Disease ◽  
Sjögren‘S Syndrome

ObjectiveTo describe the direct and indirect cost estimates of dry eye disease (DED), stratified by disease severity, and the impact of DED on quality of life (QoL) in Canadian patients.Methods and analysisA prospective, multicentre, observational, cross-sectional study was conducted at six sites across Canada. Eligible patients completed a 20 min survey on demography, general health, disease severity, QoL and direct (resource utilisation and out-of-pocket expenses for the past 3–24 months) and indirect costs (absenteeism and presenteeism based on Work Productivity and Activity Impairment questionnaire responses). Subgroup analyses were performed according to DED severity and presence of Sjögren’s syndrome.ResultsResponses from 146 of 151 participants were included in the analysis. DED was rated as moderate or severe by 19.2% and 69.2% of patients, respectively. Total mean annual costs of DED were $C24 331 (Canadian dollars) per patient and increased with patient-reported disease severity. Mean (standard deviation [SD]) indirect costs for mild, moderate and severe disease were $C5961 ($C6275), $C16 525 ($C11 607), and $C25 485 ($C22,879), respectively. Mean (SD) direct costs were $C958 ($C1216), $C1303 ($C1574) and $C2766 ($C7161), respectively. QoL scores were lowest in patients with Sjögren’s syndrome (8.2% of cohort) and those with severe DED.ConclusionThis study provides important insights into the negative impact of DED in a Canadian setting. Severe DED was associated with higher direct and indirect costs and lower QoL compared with those with mild or moderate disease. Increased costs and poorer QoL were also evident for patients with DED plus Sjögren’s syndrome versus DED alone.

Swallowing Disorders in Sjögren’s Syndrome: Prevalence, Risk Factors, and Effects on Quality of Life

Dysphagia ◽  
2015 ◽  
Vol 31 (1) ◽  
pp. 49-59 ◽  
Author(s):  
Jenny L. Pierce ◽  
Kristine Tanner ◽  
Ray M. Merrill ◽  
Karla L. Miller ◽  
Katherine A. Kendall ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Risk Factors ◽  
Sjögren’S Syndrome ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Swallowing Disorders ◽  
Sjögren‘S Syndrome
Sign in / Sign up

Export Citation Format

Share Document